369 related articles for article (PubMed ID: 17620372)
1. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
Julian K; Kosowska-Shick K; Whitener C; Roos M; Labischinski H; Rubio A; Parent L; Ednie L; Koeth L; Bogdanovich T; Appelbaum PC
Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
Pillai SK; Gold HS; Sakoulas G; Wennersten C; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 2007 Jun; 51(6):2223-5. PubMed ID: 17404001
[TBL] [Abstract][Full Text] [Related]
3. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus.
Hageman JC; Patel J; Franklin P; Miscavish K; McDougal L; Lonsway D; Khan FN
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):440-2. PubMed ID: 18842378
[TBL] [Abstract][Full Text] [Related]
5. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
Boucher HW; Sakoulas G
Clin Infect Dis; 2007 Sep; 45(5):601-8. PubMed ID: 17682996
[TBL] [Abstract][Full Text] [Related]
7. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
Camargo IL; Neoh HM; Cui L; Hiramatsu K
Antimicrob Agents Chemother; 2008 Dec; 52(12):4289-99. PubMed ID: 18824611
[TBL] [Abstract][Full Text] [Related]
8. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
[TBL] [Abstract][Full Text] [Related]
9. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
Kelley PG; Gao W; Ward PB; Howden BP
J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N
Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830
[No Abstract] [Full Text] [Related]
12. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
Mariani PG; Sader HS; Jones RN
J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
[No Abstract] [Full Text] [Related]
13. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
Rose WE; Rybak MJ; Tsuji BT; Kaatz GW; Sakoulas G
J Antimicrob Chemother; 2007 Jun; 59(6):1190-3. PubMed ID: 17434881
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus.
Yang SJ; Kreiswirth BN; Sakoulas G; Yeaman MR; Xiong YQ; Sawa A; Bayer AS
J Infect Dis; 2009 Dec; 200(12):1916-20. PubMed ID: 19919306
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
Cui L; Tominaga E; Neoh HM; Hiramatsu K
Antimicrob Agents Chemother; 2006 Mar; 50(3):1079-82. PubMed ID: 16495273
[TBL] [Abstract][Full Text] [Related]
16. [The second life of daptomycin: analysis of a successful come-back].
Decousser JW; Doucet Populaire F
Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200
[No Abstract] [Full Text] [Related]
17. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Mangili A; Bica I; Snydman DR; Hamer DH
Clin Infect Dis; 2005 Apr; 40(7):1058-60. PubMed ID: 15825002
[TBL] [Abstract][Full Text] [Related]
18. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, meticillin-resistant Staphylococcus aureus in a patient with chronic kidney disease.
Kuo CC; Wu VC; Huang YT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2009 Jan; 33(1):96-8. PubMed ID: 18790610
[No Abstract] [Full Text] [Related]
19. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia.
Naimi TS; Anderson D; O'Boyle C; Boxrud DJ; Johnson SK; Tenover FC; Lynfield R
Clin Infect Dis; 2003 Jun; 36(12):1609-12. PubMed ID: 12802763
[TBL] [Abstract][Full Text] [Related]
20. Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.
Gaupp R; Lei S; Reed JM; Peisker H; Boyle-Vavra S; Bayer AS; Bischoff M; Herrmann M; Daum RS; Powers R; Somerville GA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4226-38. PubMed ID: 25963986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
